csirt@kutim:~/threat-intel/cve/CVE-2023-41332

Katalog CVE

CVSS 3.5 · Low EPSS 0,51%

Kerentanan Improper Handling of Exceptional Conditions pada cilium. Skor CVSS 3.1 3.5 (Low) menurut NVD.

Deskripsi (NVD)

Cilium is a networking, observability, and security solution with an eBPF-based dataplane. In Cilium clusters where Cilium's Layer 7 proxy has been disabled, creating workloads with `policy.cilium.io/proxy-visibility` annotations (in Cilium >= v1.13) or `io.cilium.proxy-visibility` annotations (in Cilium <= v1.12) causes the Cilium agent to segfault on the node to which the workload is assigned. Existing traffic on the affected node will continue to flow, but the Cilium agent on the node will not able to process changes to workloads running on the node. This will also prevent workloads from being able to start on the affected node. The denial of service will be limited to the node on which the workload is scheduled, however an attacker may be able to schedule workloads on the node of their choosing, which could lead to targeted attacks. This issue has been resolved in Cilium versions 1.14.2, 1.13.7, and 1.12.14. Users unable to upgrade can avoid this denial of service attack by enabling the Layer 7 proxy.

Rincian

Terbit di NVD
27 September 2023
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
3.5 (Low), sumber NVD
CVSS:3.1/AV:A/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:L · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-755: Improper Handling of Exceptional Conditions
EPSS (30 hari)
0,51% peluang dieksploitasi; lebih tinggi dari 42,1% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
cilium cilium Semua versi sebelum 1.12.14
cilium cilium Versi 1.13.0 hingga sebelum 1.13.7
cilium cilium Versi 1.14.0 hingga sebelum 1.14.2

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.